230 related articles for article (PubMed ID: 23976996)
1. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
Suzuki N; Kunishima S; Ikejiri M; Maruyama S; Sone M; Takagi A; Ikawa M; Okabe M; Kojima T; Saito H; Naoe T; Matsushita T
PLoS One; 2013; 8(8):e71187. PubMed ID: 23976996
[TBL] [Abstract][Full Text] [Related]
2. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
Zhang Y; Conti MA; Malide D; Dong F; Wang A; Shmist YA; Liu C; Zerfas P; Daniels MP; Chan CC; Kozin E; Kachar B; Kelley MJ; Kopp JB; Adelstein RS
Blood; 2012 Jan; 119(1):238-50. PubMed ID: 21908426
[TBL] [Abstract][Full Text] [Related]
3. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
[TBL] [Abstract][Full Text] [Related]
4. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
[TBL] [Abstract][Full Text] [Related]
5. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
[TBL] [Abstract][Full Text] [Related]
6. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of
Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
[No Abstract] [Full Text] [Related]
8. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
Kunishima S
Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
[TBL] [Abstract][Full Text] [Related]
9. Association of a novel in-frame deletion mutation of the MYH9 gene with end-stage renal failure: case report and review of the literature.
Ishida M; Mori Y; Ota N; Inaba T; Kunishima S
Clin Nephrol; 2013 Sep; 80(3):218-22. PubMed ID: 22541678
[TBL] [Abstract][Full Text] [Related]
10.
Kanematsu T; Suzuki N; Tamura S; Suzuki A; Ishikawa Y; Katsumi A; Kiyoi H; Saito H; Kunishima S; Kojima T; Matsushita T
Nagoya J Med Sci; 2021 Feb; 83(1):75-86. PubMed ID: 33727739
[No Abstract] [Full Text] [Related]
11. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder.
Wasano K; Matsunaga T; Ogawa K; Kunishima S
Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3547-3552. PubMed ID: 26942920
[TBL] [Abstract][Full Text] [Related]
12. A De Novo Mutation in MYH9 in a Child With Severe and Prolonged Macrothrombocytopenia.
Li K; Jin R; Xu W; Shen Y; Lu K; Wu X
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e7-e10. PubMed ID: 32520844
[TBL] [Abstract][Full Text] [Related]
13. Renal manifestations of patients with MYH9-related disorders.
Han KH; Lee H; Kang HG; Moon KC; Lee JH; Park YS; Ha IS; Ahn HS; Choi Y; Cheong HI
Pediatr Nephrol; 2011 Apr; 26(4):549-55. PubMed ID: 21210153
[TBL] [Abstract][Full Text] [Related]
14. Macrothrombocytopenia With Congenital Bilateral Cataracts: A Phenotype of MYH9 Disorder With Exon 24 Indel Mutations.
Aoki T; Kunishima S; Yamashita Y; Minamitani K; Ota S
J Pediatr Hematol Oncol; 2018 Jan; 40(1):76-78. PubMed ID: 29200148
[TBL] [Abstract][Full Text] [Related]
15. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.
Pecci A; Ma X; Savoia A; Adelstein RS
Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
[TBL] [Abstract][Full Text] [Related]
16. Linking the Landscape of
Asensio-Juárez G; Llorente-González C; Vicente-Manzanares M
Cells; 2020 Jun; 9(6):. PubMed ID: 32545517
[TBL] [Abstract][Full Text] [Related]
17. Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene.
Seri M; Savino M; Bordo D; Cusano R; Rocca B; Meloni I; Di Bari F; Koivisto PA; Bolognesi M; Ghiggeri GM; Landolfi R; Balduini CL; Zelante L; Ravazzolo R; Renieri A; Savoia A
Hum Genet; 2002 Feb; 110(2):182-6. PubMed ID: 11935325
[TBL] [Abstract][Full Text] [Related]
18. [Gene analysis and clinical features of MYH9-related disease].
Luo XJ; Cao K; Liu J; Duan QY; Chen SY; Zhang Y; Huang T; Mao XN; Li CG; Chen YS
Zhonghua Er Ke Za Zhi; 2021 Nov; 59(11):957-962. PubMed ID: 34711031
[No Abstract] [Full Text] [Related]
19. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
Sun XH; Wang ZY; Yang HY; Cao LJ; Su J; Yu ZQ; Bai X; Ruan CG
Acta Haematol; 2013; 129(2):106-13. PubMed ID: 23207509
[TBL] [Abstract][Full Text] [Related]
20. Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA.
Kahr WH; Savoia A; Pluthero FG; Li L; Christensen H; De Rocco D; Traivaree C; Butchart SE; Curtin J; Stollar EJ; Forman-Kay JD; Blanchette VS
Thromb Haemost; 2009 Dec; 102(6):1241-50. PubMed ID: 19967157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
